Evaluating predisposing factors and anaesthetic challenges in the emerging problem of mucormycosis in post COVID-19 patients: Retrospective cohort study

Kavita Lalchandani; Afroza Syed; Vedant Lalchandani; Hetal Kotecha; Azara Patel

doi:10.53730/ijhs.v6nS3.8098

Authors

Kavita Lalchandani Associate professor in Anaesthesiology, BMC (Baroda medical college), Baroda | L-6/ A Premdasnagar society, Warashiya ring road, Vadodara
Afroza Syed Assistant professor in Anaesthesiology, BMC, Baroda
Vedant Lalchandani Ex intern doctor, GMERS, Gotri, Vadodara
Hetal Kotecha Ex third year resident, BMC, Baroda
Azara Patel 2nd year resident, BMC Baroda, Vadodara, Gujarat, India

Keywords:

rhino-orbito-cerebral mucormycosis, diabetes mellitus, anaesthetic challenges, difficult airway

Abstract

Background and Objectives: The epidemic of Mucormycosis came hovering like a tsunami in Covid- 19 recovered patients during second wave of the pandemic.. Mucormycosis is a rapidly progressive, angio-invasive, opportunistic fungal infection commonly caused by Rhizopus and mucor species. Mucormycosis can affect any organ system and pose several problems like uncontrolled diabetes, unstable hemodynamics, immunosuppression and difficult airway. Our study aimed to evaluate the predisposing factors and anaesthetic challenges encountered in Rhino-orbito-cerebral mucormycosis(ROCM) taken for surgical intervention under anaesthesia. Method: A retrospective, cohort study where we evaluated 100 covid-19 recovered patients who underwent surgical resection for ROCM under general anaesthesia. Hospital records of each patient were reviewed for demographic details, comorbid conditions, treatment modalities, covid associated organ damage, hemodynamics, surgical procedures, anaesthetic technique, and mortality. Results: Demographic data showed a male preponderance with 67 males and 33 females in the age group of 25-74yrs. 68 patients were ASA grade 3, 31 patients were ASA grade 4 and 1 patient was ASA grade5. Comorbid conditions showed 78 patients had DM, 8 patients had hypertension, while 14 had both.

Downloads

Download data is not yet available.

References

Rajeev Soman1, Ayesha Sunavala2 Post COVID-19 Mucormycosis - from the Frying Pan into the Fire Journal of the Association of Physicians of India January 2021 volume 69

E Karaaslan Anesthetic management of rhinoorbitocerebral mucormycosis; Focus on challenges J. Mycol Med. 2019 Sep;29(3):219-222.

Awadhesh Kumar Singh aRitu Singha Shashank R. Joshib Anoop Misracde : Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India Diabetes & Metabolic Syndrome: Clinical Research & Reviews , Volume 15, Issue 4, July–August 2021, 102146

Ritu Arora, 1 Ruchi Goel, 1 Samreen Khanam, 1 et al. Rhino-Orbito-Cerebral-Mucormycosis During the COVID-19 Second wave in 2021 – A Preliminary Report from a Single Hospital Clin Ophthalmol. 2021; 15: 3505–3514.

Naveen Malhotra, Sukhminder Jit Singh Bajwa,1 Muralidhar Joshi,2 Lalit Mehdiratta,3 and Madhuri Kurdi4 :Second wave of COVID-19 pandemic and the surge of mucormycosis: Lessons learnt and future preparedness: Indian Society of Anaesthesiologists (ISA National) Advisory and Position Statement IJA Indian J Anaesth. 2021 Jun; 65(6): 427–433.

Atul Vyas, Isha shah et al : Anaesthetic considerations for post covid mucormycosis surgery: Focus on challenges- A retrospective study International journal of scientific research volume 10 issue 10 54 -56 October 2021

Code Mucor: Guidelines for the Diagnosis, Staging and Management of Rhino-Orbito-Cerebral Mucormycosis in the Setting of COVID-19 June2021 Indian Journal of Ophthalmology Volume 69 Issue 6 1361-1364

Prenissl J, Jaacks LM, Mohan V, et al. Variation in health system performance for managing diabetes among states in India: a cross-sectional study of individuals aged 15 to 49 years. BMC Med 2019; 17:92.

Ameet Dravid, Reema Kashiva,2 Zafer Khan,3Balasaheb Bande3 et al.: Epidemiology, clinical presentation and management of COVID- 19 associated mucormycosis: A single centre experience from Pune, Western India. Mycoses (Wylie online library) Feb 2022 volume 65, issue 5, page no. 526-540

Prakash H, Chakrabarti A. Global Epidemiology of Mucormycosis. J Fungi (Basel) 2019; 5:26.

Chakrabarti A, Kaur H, Savio J, et al. Epidemiology and clinical outcomes of invasive mould infections in Indian intensive care units (FISF study). J Crit Care 2019; 51:64-70.

Ibrahim AS, Spellberg B, Walsh TJ, et al Pathogenesis of mucormycosis..Clin Infect Dis 2012; 54 (Suppl 1):S16-22.

Kathy H, Tony A, Matthew J, et al. A case of invasive pulmonary mucormycosis resulting from short courses of corticosteroids in a well-controlled diabetic patient. Medical Mycology Case Reports 2020; 29:22-24

Prasad K. Kulkarni, Narasimha B. Reddy, B. Shrinivas1, Vinita V. Takkalki. Anesthetic considerations in the management of mucormycosis: International journal of Medicine and public health.vol.5issue4, Oct-Dec2015

COVID-19 associated mucormycosis: Staging and management recommendations (Report of a multi-disciplinary expert committee) Hardeep Singh Malhotra , Prashant Gupta et al. Journal of Oral Biology and Craniofacial Research Volume 11, Issue 4, October–December 2021, Pages 569-580

Suhas Ashok Hooli, Vaijayanti Nitin Gadre, Sunita Bage,1 and Manoj Dnyanba Gilvarkar: The aftermath of COVID-19 pandemic: Rhino-orbital mucormycosis Indian J Anaesth. 2021 Jul; 65(7): 548–553.